🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We're excited to present at #ASGCT2025 this week live in New Orleans & virtually! 📅May 13: Kalpana Rajanala on OCU410-ST for Stargardt Disease. 📅May 14: Pushpendra Singh on OCU400 for RP. 🔗annualmeeting.asgct.org. #GeneTherapy #RetinitisPigmentosa #StargardtDisease

From Utah to Florida, we shared breakthrough data and connected with leaders at #Eyecelerator, #ARVO2025 & #RetinaWorldCongress. Thanks to Drs. Bakall, Shah, Haider & Maldonado for representing Ocugen. 🎥 bit.ly/43oF0sG. #ModifierGeneTherapy #Ocugen

This #IRDAwareness & #GeneticTesting Month, Ocugen is proud to lead the way in developing modifier gene therapies for RP & Stargardt. 🔬 Early diagnosis matters. Learn about our Phase 3 liMeliGhT trial for RP: ocugen.com/clinical-study…. #GeneTherapy #PreventBlindness

It’s #StargardtAwarenessWeek. This IRD causes vision loss and affects 100K people in the U.S. & Europe. We’re developing OCU410ST, a gene therapy candidate aimed at slowing or stopping progression. 🔗 ocugen.com/#foobox-2/0/OC…. #StargardtDisease #GeneTherapy #VisionResearch

Today, we honor the brave men and women who gave their lives in service to America. Their courage, sacrifice, and legacy will never be forgotten. #MemorialDay #HonorAndRemember

BIG NEWS! The U.S. FDA has granted Rare Pediatric Disease Designation to OCU410ST for the treatment of Stargardt disease. A big step forward in fighting inherited vision loss. 👁️ Read more here: bit.ly/3H8Vmhl. #Ocugen #GeneTherapy #FDA

Ocugen is breaking barriers in clinical trials with a gene-agnostic approach that has the potential to restore vision for those with inherited retinal diseases. Learn more from CMO Huma Qamar, MD, MPH, CMI's interview with Clinical Leader: bit.ly/3Z5WbOh. #IRDs #Biotech

Grateful to Dr. Rishi P. Singh MD and Ocular Surgery News for covering U.S. FDA's Rare Pediatric Disease Designation for OCU410ST, our modifier gene therapy candidate for Stargardt disease. 📰 Read more: bit.ly/3Zf5HyK. 📢 Press release: bit.ly/3H8Vmhl. #Stargardt #GeneTherapy

Ocugen licenses OCU400 gene therapy to a well-established Korean pharma partner up to $11M in upfront/near-term payments and $150M in sales milestones. With 15K RP patients in Korea, we’re expanding our global impact. More: bit.ly/3FPnHca. #GeneTherapy #RP #OCU400

Excited to share that Dr. David Almeida MD will co-moderate and present on OCU400 gene therapy at #SOE2025 in Lisbon! Don’t miss his talk on the 2-year Phase 1/2 RP trial results on Monday, June 9, 2:30 – 4:00 PM! More on this event: soe2025.soevision.org. #GeneTherapy #SOE2025

We’re headed to #BIO2025 in Boston! Our CEO, Dr. Shankar Musunuri, will highlight how our modifier gene therapy platform aims to rewrite the future of rare disease treatment. Biotechnology Innovation Organization 🔗 bit.ly/3HA7wAe. #Ocugen #ModiferGeneTherapy

Today, Ocugen honors fathers and father figures for their leadership, commitment, sacrifice and most importantly—love. Thank you for all you do to ensure your children see a brighter, heathier tomorrow. Happy Father’s Day. #FathersDay

#BIO2025 is off to a great start! #Ocugen #GeneTherapy

From media interviews to meaningful panel presentations, #BIO2025 gave us the chance to share how #Ocugen’s gene therapy platform is leading the way in retinal innovation. Grateful for the connections and collaboration driving biotech forward. #GeneTherapy #RetinalInnovation

Dr. Lejla Vajzovic will speak on modifier gene therapy for inherited retinal disease at #CTSatSummit, today, Saturday, June 21, 2025. Learn more: ctsretina.org. #GeneTherapy #Stargardt #IRDs #Retina

Ocugen’s OrthoCellix is merging with Carisma Therapeutics! The new company will advance NeoCart® into Phase 3 for knee cartilage repair, while Ocugen focuses on gene therapy breakthroughs. Read more: bit.ly/3HUmvoB. #Biotech #NeoCart #GeneTherapy

We are excited about what the OrthoCellix announcement means for Ocugen. This strategic move adds value for stockholders without dilution of Ocugen stock. The value of OrthoCellix is estimated at $135 million. Read more: bit.ly/3HUmvoB #NeoCart #Biotech

300,000 people in the U.S. & Europe are living with retinitis pigmentosa. Our Phase 3 #OCU400 liMeliGhT trial is the only gene-agnostic therapy in development. Now enrolling. Learn more: NCT06388200 | [email protected] #GeneTherapy #RP #ClinicalTrials

Excited to share that Arun Upadhyay, #Ocugen’s CSO, will present at #CGT2025 in Orlando on Monday, July 7! He’ll spotlight the modifier gene therapy platform how we’re advancing treatment for major blindness diseases. 🔗 cgtsummit.unitedscientificgroup.org #GeneTherapy #Biotech

This #IndependenceDay, we celebrate the courage and liberty that unite us as a nation. From all of us at Ocugen, have a safe and joyful #FourthofJuly with your loved ones.